Trials / Completed
CompletedNCT03956953
Single and Multiple Dose Pharmacokinetics of BMS-986165 in a Randomized, Double-Blind, Placebo-Controlled Study in Healthy Chinese Subjects
A Randomized, Double-Blind, Placebo-Controlled, Single- And Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BMS-986165 in Healthy Chinese Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 135 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
Main objective of this study is to assess BMS-986165 plasma PK following single and multiple oral doses of BMS-986165 in healthy Chinese subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986165 | Dose 1 or Dose 2 on Day 1, and from Days 5-19' |
| OTHER | Placebo | Placebo matching Dose 1 or Dose 2 on Day 1, and from Days 5-19 |
Timeline
- Start date
- 2019-04-04
- Primary completion
- 2019-09-25
- Completion
- 2019-09-25
- First posted
- 2019-05-21
- Last updated
- 2020-06-18
Locations
1 site across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03956953. Inclusion in this directory is not an endorsement.